Ubs Oconnor LLC Beam Therapeutics Inc. Call Options Transaction History
Ubs Oconnor LLC
- $1.51 Billion
- Q4 2024
Call Options
2 transactions
Others Institutions Holding BEAM
# of Institutions
253Shares Held
78.6MCall Options Held
304KPut Options Held
142K-
Farallon Capital Management LLC San Francisco, CA8.24MShares$218 Million1.09% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$202 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$201 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$187 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$120 Million70.85% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.86B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...